Nama's AI scorecard currently rates GoodRx Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is GDRX's P/E ratio?

GoodRx trades at a trailing price-to-earnings ratio of 11.0.

When does GDRX report earnings?

GoodRx's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $0.08.

What is the GDRX price target?

The median analyst price target from 12 analysts is $4.00, with a range of $2.65 – $5.00.

Is GDRX Shariah compliant?

Nama's AAOIFI-style screen reads GoodRx as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

GoodRx (GDRX)

Healthcare · Health Information Services · NASDAQ

GoodRx (GDRX) is a Healthcare company in the Health Information Services industry. It has a market capitalization of $1.20B, a trailing price-to-earnings ratio of 11.0 and a free-cash-flow yield of 7.4%. Over the most recent reported fiscal year, revenue grew 0.6% and free cash flow per share fell 9.2%. Nama's AI scorecard rates it Buy, 6.6 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Buy · 6.6/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Middle · +2.9% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-92.0%

How far the last close sits under the highest price of the past five years.

Market cap	$1.20B
Trailing P/E	11.0
Price / book	1.9
Price / sales	1.5
FCF yield	7.4%
Dividend yield	—
Gross margin	90.8%
Operating margin	9.5%
Net margin	2.1%
Revenue growth (YoY)	+0.6%
Revenue growth (3-yr annual)	+1.3%
EPS growth (YoY)	+6.1%
FCF/share growth (YoY)	-9.2%
Beta	1.7
Exchange	NASDAQ
Sector	Healthcare
Industry	Health Information Services

GDRX earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate $0.08). Beat the EPS estimate in 0 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 5, 2026	$0.08	$0.08	+0.0%	$200.41M
Q1 2026	May 6, 2026	$0.07	$0.07	+0.0%	$194.01M
Q4 2025	Feb 25, 2026	$0.09	$0.09	+0.0%	$194.78M
Q3 2025	Nov 4, 2025	$0.08	$0.09	-11.1%	$196.03M

GDRX analyst price target

Median target $4.00 from 12 analysts, ranging $2.65 – $5.00.

Health Information Services peers

Ticker	Company	Market cap	P/E
VEEV	Veeva Systems	$49.18B	35.0
TEM	Tempus AI	$13.87B	—
BTSG	BrightSpring Health Services	$13.36B	39.3
HNGE	Hinge Health	$9.34B	51.7
HQY	HealthEquity	$8.57B	23.3
TXG	10x Genomics	$7.72B	296.4
DOCS	Doximity	$5.79B	23.7
WAY	Waystar	$5.45B	17.2

Explore live GDRX data on Nama Insights →

GDRX FAQ

Is GDRX a buy?: Nama's AI scorecard currently rates GoodRx Buy (6.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is GDRX's P/E ratio?: GoodRx trades at a trailing price-to-earnings ratio of 11.0.
When does GDRX report earnings?: GoodRx's next scheduled report is on Nov 9, 2026. Analysts expect EPS of $0.08.
What is the GDRX price target?: The median analyst price target from 12 analysts is $4.00, with a range of $2.65 – $5.00.
Is GDRX Shariah compliant?: Nama's AAOIFI-style screen reads GoodRx as Not Shariah Compliant. At least one of the three ratios or the industry test failed.